Scholarlink

<p>The presence of bone marrow (BM) disseminated tumor cells (DTC<sub>bm</sub>) identifies early-stage breast cancer patients at increased risk of recurrence and poorer overall survival. However, limitations in detecting DTC<sub>bm</sub> by standard immunohistochemical approaches have hampered clinical application. To address this gap, we developed a flow cytometry-based method, DTC-Flow, that enables the sensitive and efficient detection and molecular characterization of breast cancer DTC<sub>bm</sub>. Our analysis identified HER2 as a sensitive marker for detecting breast cancer cells, including those lacking <i>HER2</i> amplification are claudin-low. DTC-Flow using a HER2/EpCAM/CD45 marker panel enabled &gt;90% cancer cell recovery and sensitivity of one cancer cell per million nucleated BM cells across a range of breast cancer subtypes. Molecular analyses of DTC-Flow-sorted DTC<sub>bm</sub> from metastatic patients suggested a quiescent state and demonstrated their close genomic relationship to primary/metastatic tumors, as well as continued genetic evolution. In early-stage breast cancer patients, DTC-Flow detected DTC<sub>bm</sub> with greater sensitivity than cytokeratin-based immunohistochemical approaches. Our data support the development of DTC-Flow as a sensitive and specific platform to identify breast cancer patients harboring DTC<sub>bm</sub> and better understand the biology of minimal residual disease. Ultimately, this platform could enable the selection of personalized therapeutic approaches based on molecular features of DTC<sub>bm</sub>, monitoring of DTC<sub>bm</sub> to assess the efficacy of such therapies, and the development of novel therapeutic approaches targeting unique biological vulnerabilities of DTCs in order to eradicate these cells before they can give rise to lethal recurrent cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Elizabeth M. Chislock,
  • Tien-chi Pan,
  • Dhruv Pant,
  • Yan Chen,
  • George Woodfield,
  • Jewell Graves,
  • Matthew R. Lawrence-Paul,
  • George K. Belka,
  • Jianping Wang,
  • Lauren Bayne,
  • Tatiana Blanchard,
  • Meaghan Smith,
  • Xiaodan Ji,
  • Natalie N. C. Shih,
  • Danielle Soucier-Ernst,
  • Noah Goodman,
  • Isoris Nivar,
  • Brooke Goodspeed,
  • Shannon DeLuca,
  • John Ndicu,
  • Candace Clark,
  • Melissa Langer,
  • S. William Stavropoulos,
  • William DeMuth,
  • Andrew Morschauser,
  • William Murphy,
  • Anupma Nayak,
  • Michael Feldman,
  • Amy Clark,
  • Liping Yu,
  • Kevin Judge,
  • Scott Bornheimer,
  • Charles H. Pletcher Jr.,
  • Jonni S. Moore,
  • Angela DeMichele,
  • Lewis A. Chodosh

摘要

The presence of bone marrow (BM) disseminated tumor cells (DTCbm) identifies early-stage breast cancer patients at increased risk of recurrence and poorer overall survival. However, limitations in detecting DTCbm by standard immunohistochemical approaches have hampered clinical application. To address this gap, we developed a flow cytometry-based method, DTC-Flow, that enables the sensitive and efficient detection and molecular characterization of breast cancer DTCbm. Our analysis identified HER2 as a sensitive marker for detecting breast cancer cells, including those lacking HER2 amplification are claudin-low. DTC-Flow using a HER2/EpCAM/CD45 marker panel enabled >90% cancer cell recovery and sensitivity of one cancer cell per million nucleated BM cells across a range of breast cancer subtypes. Molecular analyses of DTC-Flow-sorted DTCbm from metastatic patients suggested a quiescent state and demonstrated their close genomic relationship to primary/metastatic tumors, as well as continued genetic evolution. In early-stage breast cancer patients, DTC-Flow detected DTCbm with greater sensitivity than cytokeratin-based immunohistochemical approaches. Our data support the development of DTC-Flow as a sensitive and specific platform to identify breast cancer patients harboring DTCbm and better understand the biology of minimal residual disease. Ultimately, this platform could enable the selection of personalized therapeutic approaches based on molecular features of DTCbm, monitoring of DTCbm to assess the efficacy of such therapies, and the development of novel therapeutic approaches targeting unique biological vulnerabilities of DTCs in order to eradicate these cells before they can give rise to lethal recurrent cancers.